Overview
?
Jian Zhi, Jerry Wang
See more contacts
Scientific Research and Development Services
,
Pharmaceutical and Medicine Manufacturing
,
Drugs and Druggists' Sundries Merchant Wholesalers
,
Biological research
,
Pharmaceutical preparations
See All Industries , Drugs, proprietaries, and sundries Medical research, commercial
See Fewer Industries
See All Industries , Drugs, proprietaries, and sundries Medical research, commercial
See Fewer Industries
Accounting, Tax Preparation, Bookkeeping, and Payroll Services
,
Advertising, Public Relations, and Related Services
,
Architectural, Engineering, and Related Services
,
Computer Systems Design and Related Services
,
Legal Services
,
Management, Scientific, and Technical Consulting Services
,
Other Professional, Scientific, and Technical Services
,
Specialized Design Services
?
?
?
Actual
?
Actual
$5.16 million
Actual
-46.72%
$2,163
DEC
?
?
GreTai:6875
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2024 (12 month period) in USD
Annual Revenue 2024
$5.16 million
USD
Actual
1 USD = 32.4834 TWD
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | -$4 | $1 | -$8 |
| Net Investing Cash | -$32 | -$3 | -$0 |
| Net Financing Cash | $29 | $11 | $15 |
| Net Change in Cash | -$7 | $9 | $6 |
| Cash at Beginning of Period | $30 | $21 | $14 |
| Cash at End of Period | $23 | $30 | $21 |
| Capital Expenditure | -$5 | -$3 | -$0 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $23 | $30 | $21 |
| Accounts Receivable | $0 | $ | $ |
| Inventories | $1 | $1 | $ |
| Other Current Assets | $28 | $0 | $0 |
| Asset Summary | |||
| Total Current Assets | $52 | $31 | $21 |
| Tangible Fixed Assets | $10 | $6 | $1 |
| Intangible Assets | $ | $ | $ |
| Total Assets | $2,164 | $1,334 | $799 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $0 | $0 | $ |
| Short-Term Debt | $ | $0 | $0 |
| Other Current Liabilities | $4 | $2 | $1 |
| Liability Summary | |||
| Total Current Liabilities | $4 | $2 | $1 |
| Long-Term Debt | $ | $0 | $0 |
| Other Long-Term Liabilities | $ | $ | $ |
| Total Liabilities | $7 | $6 | $1 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $20 | $18 | $17 |
| Retained Earnings | -$5 | $0 | -$30 |
| Equity Summary | |||
| Total Equity | $60 | $35 | $23 |
| Shares Outstanding | 129,086,404 | 117,204,004 | 113,424,811 |